Clinical Trial Update: UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly [Phase 2]

View source ↗

Summary

This clinical trial update covers a Phase 2 study of Unity MR-Linac adaptive hypofractionated boost for high-grade glioma in elderly patients, sponsored by Sunn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Idh-mutant Glioblastoma

Drugs mentioned

• Unity MR-Linac

Snippet

Sponsor: Sunnybrook Health Sciences Centre | Conditions: Glioblastoma Multiforme, Adult, Glioblastoma, IDH-mutant | Phase 2 | Status: ACTIVE_NOT_RECRUITING